Skip to main content
Publications
Strober B, Blauvelt A, Zhao Y, Milutinovic M, Mollon P, You R, Sherif B, Williams N, Fox T, Augustin M, Lebwohl M. Secukinumab treatment provides more effective relief from patient-reported psoriasis-related pain, itching, and scaling than ustekinumab. Poster presented at the 35th Anniversary Fall Clinical Dermatology Conference; October 20, 2016. Las Vegas, NV. Previously presented at the 24th European Academy of Dermatology and Venereology Congress.
Blauvelt A, Korman N, Mollon P, Zhou Y, Milutinovic M, You R, Sherif B, Williams N, Fox T, Augustin M. Secukinumab treatment provides faster and more effective relief from patient-reported quality of life impact than ustekinumab in subjects with moderate to severe plaque psoriasis. Poster presented at the 35th Anniversary Fall Clinical Dermatology Conference; October 20, 2016. Las Vegas, NV. Previously presented at the 24th European Academy of Dermatology and Venereology Congress.
Zheng S, D'Souza VK, Bartis D, Dancer RC, Parekh D, Naidu B, Gao-Smith F, Wang Q, Jin S, Lian Q, Thickett DR. Lipoxin A4 promotes lung epithelial repair whilst inhibiting fibroblast proliferation. ERJ Open Res. 2016 Oct 3;2(3). doi: 10.1183/23120541.00079-2015
Taylor S, Demeyin (Nuabor) W, Muls A, Ferguson C, Farnell DJ, Cohen D, Andreyev J, Green J, Smith L, Ahmedzai S, Pickett S, Nelson A, Staffurth J. Improving the well-being of men by Evaluating and Addressing the Gastrointestinal Late Effects (EAGLE) of radical treatment for prostate cancer: study protocol for a mixed-method implementation project. BMJ Open. 2016 Oct 3;6(10):e011773. doi: 10.1136/bmjopen-2016-011773
Mease P, Schwab PE, Dinh H, Sheer R, Cappelleri J, Bananis E, Harnett J, Hsu MA. Treatment patterns, health care resource utilization, and costs associated with psoriatic arthritis among Humana commercial and Medicare member populations. Poster presented at the 2016 Academy of Managed Care Pharmacy's 28th Annual Meeting & Expo; October 3, 2016. National Harbor, MD.
Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherril B, Ruiz-Soto R, Kaye JA, Hamadani M. Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis. J Oncol Pharm Pract. 2016 Oct;22(5):666-78. doi: 10.1177/1078155215603230
Chertow GM, Liu J, Monda KL, Gilbertson DT, Brookhart MA, Beaubrun AC, Winkelmayer WC, Pollock A, Herzog CA, Ashfaq A, Sturmer T, Rothman KJ, Bradbury BD, Collins AJ. Epoetin alfa and outcomes in dialysis amid regulatory and payment reform. J Am Soc Nephrol. 2016 Oct;27(10):3129-38. doi: 10.1681/ASN.2015111232
Kenter JO, Bryce R, Christie M, Cooper N, Hockley N, Irvine KN, Fazey I, O'Brien L, Orchard-Webb J, Ravenscroft N, Raymond CM, Reed MS, Tett P, Watson V. Shared values and deliberative valuation: future directions. Ecosyst Serv. 2016 Oct;21(Part B):358-71. doi: 10.1016/j.ecoser.2016.10.006
Basagana X, Esnaola M, Rivas I, Amato F, Alvarez-Pedrerol M, Forns J, Lopez-Vicente M, Pujol J, Nieuwenhuijsen M, Querol X, Sunyer J. Neurodevelopmental deceleration by urban fine particles from different emission sources: a longitudinal observational study. Environ Health Perspect. 2016 Oct;124(10):1630-6.
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M, Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo. Poster presented at the Maui Derm NP+ PA Fall 2016; September 29, 2016. Asheville, NC. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B, Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis. Poster presented at the Maui Derm NP+ PA Fall 2016; September 29, 2016. Asheville, NC. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B, McLeod L, Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis. Poster presented at the Maui Derm NP+ PA Fall 2016; September 29, 2016. Asheville, NC. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Hoffman E, Mladsi DM, Cryer B, Hopkins W, Brater DC, Parikh R, Goyal R, Castellsague J, Stafkey-Mailey D, Young C. Dose-related risks of cardiovascular, gastrointestinal, and renal adverse events associated with meloxicam among patients with osteoarthritis: an observational study using US claims data. Poster presented at the 2016 ACR/ARHP Annual Meeting; November 15, 2016. Washington, DC. [abstract] Arthritis Rheumatol. 2016 Sep 28; 68(Suppl 10).
Gottlieb AB, Pariser D, Tsai TF, Pinter A, Zhou Y, Gilloteau I, Mordin M, Davenport E, Guana A, Reich K. Secukinumab provides greater 52-week sustained relief in dermatology-specific quality-of-life impact than ustekinumab. Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Strober B, Jazayeri S, Thaci D, Augustin M, Zhou Y, Gilloteau I, McLeod LD, Sherif B, Herrera V, Nyirady J, Guana A, Lebwohl M. Secukinumab provides faster and more sustained 52-week complete relief from psoriasis-related pain, itching, and scaling than ustekinumab in subjects with moderate-to-severe plaque psoriasis. Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Proctor C, McBride D, Balp M-M, McLeod L, Hunter S, Tian H, Khalil S, Hollis K, Maurer M. Comparison of twice-daily and once-daily Urticaria Activity Score: results from the first international burden of illness ASSURE-CSU study in inadequately-controlled chronic spontaneous (idiopathic) urticaria. Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Vender R, Leonardi C, Puig L, Ziv M, Zhou Y, Gilloteau I, Sherif B, McLeod LD, Nyirady J, Guana A, Strober B. Secukinumab provides greater cumulative 52-week skin clearance and quality of life benefit in patients with moderate-to-severe plaque psoriasis than ustekinumab: an area under the curve analysis. Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Blauvelt A, Mehlis S, Vanaclocha F, Vender R, Zhao Y, Gilloteau I, Davenport E, Williams N, Guana A, Tyring S. Secukinumab provides greater 52-week sustained relief from dermatology-related quality of life impact on clothing choice and sexual function than ustekinumab. Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Puig L, Sofen H, Augustin M, Abramovits W, Kingo K, Gilloteau I, Zhao Y, Mordin M, Williams N, Guana A, Korman N. Secukinumab provides greater 52-week improvements in patient-reported outcomes versus ustekinumab in patients with moderate to severe psoriasis. Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Farrar J, Rivero E, Silman A, Hochberg M, Pandhi S, Banerjee S, Kahler K, Hunter S, Candrilli S, Castellsague J. Usage patterns of diclofenac and other selected systemic NSAIDs in the United States: results from a retrospective cohort of new users. Poster presented at the IASP World Congress on Pain 2016; September 27, 2016. Yokohama, Japan.
Luo C, Sun J, Liu D, Sun B, Miao L, Musetti S, Li J, Han X, Du Y, Li L, Huang L, He Z. Self-assembled redox dual-responsive prodrug-nanosystem formed by single thioether-bridged paclitaxel-fatty acid conjugate for cancer chemotherapy. Nano Lett. 2016 Sep 14;16(9):5401-8. doi: 10.1021/acs.nanolett.6b01632
Caballero-Banos M, Benitez-Ribas D, Tabera J, Varea S, Vilana R, Bianchi L, Ayuso JR, Pages M, Carrera G, Cuatrecasas M, Martin-Richard M, Cid J, Lozano M, Castells A, Garcia-Albeniz X, Maurel J, Vilella R. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients. Eur J Cancer. 2016 Sep;64:167-74. doi: 10.1016/j.ejca.2016.06.008